Central nervous system injury meets nanoceria: opportunities and challenges

Wang Yang1,2, Maoting Zhang1, Jian He1, Mingfu Gong3, Jian Sun1,* and Xiaochao Yang1,*

1School of Biomedical Engineering and Medical Imaging, Army Medical University, Chongqing 400038, China;
2Army Health Service Training Base, Army Medical University, Chongqing 400038, China;
3Xinqiao Hospital, Army Medical University, Chongqing 400038, China

*Correspondence address. E-mail: sunjian@tmmu.edu.cn (J.S.); xcyang@tmmu.edu.cn (X.Y.)

Abstract
Central nervous system (CNS) injury, induced by ischemic/hemorrhagic or traumatic damage, is one of the most common causes of death and long-term disability worldwide. Reactive oxygen and nitrogen species (RONS) resulting in oxidative/nitrosative stress play a critical role in the pathological cascade of molecular events after CNS injury. Therefore, by targeting RONS, antioxidant therapies have been intensively explored in previous studies. However, traditional antioxidants have achieved limited success thus far, and the development of new antioxidants to achieve highly effective RONS modulation in CNS injury still remains a great challenge. With the rapid development of nanotechnology, novel nanomaterials provided promising opportunities to address this challenge. Within these, nanoceria has gained much attention due to its regenerative and excellent RONS elimination capability. To promote its practical application, it is important to know what has been done and what has yet to be done. This review aims to present the opportunities and challenges of nanoceria in treating CNS injury. The physicochemical properties of nanoceria and its interaction with RONS are described. The applications of nanoceria for stroke and neurotrauma treatment are summarized. The possible directions for future application of nanoceria in CNS injury treatment are proposed.

Keywords: nanoceria; reactive oxygen species; central nervous system injury; stroke; neurotrauma

Introduction
As a well-known catalytic metal oxide, ceria has been widely and successfully utilized in industrial catalysis, especially for the fabrication of three-way catalytic converters for vehicle exhaust gas control [1–3]. Cerium has a specific [Xe]4f15d16s2 electron configuration, where the energy of the inner 4f level is nearly equal to that of the 6s level, allowing electrons to occupy these valence subshells variably. Due to this property, cerium ions can easily and reversibly switch between valence states of Ce3+ and Ce4+. Therefore, ceria is a crystal mixture of CeO2 and Ce2O3, and could partially exchange between CeO2 and Ce2O3 with structural integrity. During the Ce4+/Ce3+ transition, the electrons from oxygen ions localize in the 4f subshell of Ce3+, accompanied by the formation of oxygen vacancies (Fig. 1a) [4, 5], rendering ceria an excellent oxygen storage capacity [6]. Moreover, when ceria particle size decreases to nanoscale, the oxygen vacancy level and Ce3+/Ce4+ ratio get a sharp increase in the crystal structure. Correspondingly, the catalytic activities of nanoceria were significantly enhanced [7, 8]. Up to now, the engineered nanoceria can be prepared by diverse synthetic processes, such as precipitation [9, 10], hydrothermal [11], microemulsion [12], green synthesis [13], sonochemical and microwave-assisted [14] methods. Accordingly, nanoceria with different sizes, shapes and catalytic activities have been produced. More comprehensive reviews on the synthesis and properties of nanoceria were published [15]. Inspired by their intriguing physicochemical properties and catalytic performances, many studies have been conducted to explore the biological effects of nanoceria. Notably, nanoceria exhibits multiple enzyme-mimetic activities (Fig. 1b), including superoxide dismutase (SOD) [16], catalase [17], peroxidase [18], oxidase [19], DNase I [20] and photolyase [21] like activities. Benefited from these activities, nanoceria has shown great potential for biomedical applications in neurology [22–24], oncology [25–27], nephrology [28–30], cardiology [34], ophthalmology [35–37], odontology [38–40], orthopedics [41–43] and others.

In the field of neurological diseases, central nervous system (CNS) injury (including stroke and neurotrauma) is associated with high morbidity and mortality worldwide [44–46]. Reactive oxygen and nitrogen species (RONS) play an important role in the...
Figure 1. (a) Nanoceria owns a fluorite structure and can change between two valence states, accompanied by the formation of the oxygen vacancies. (b) Enzyme mimetic activities and biomedical applications of nanoceria.

pathological cascade of molecular events after CNS damage [47]. Because the human brain is the most oxygen supply-dependent organ [48, 49], consuming nearly 20% of the oxygen provided by the vasculature while accounting for only ~2% of the body’s weight [50], the oxygen consumption disorder may significantly increase the RONS level in the CNS. Therefore, treatment with antioxidants can be a promising strategy against oxidative/nitrosative stress induced by RONS after CNS injury [51–53]. However, current antioxidants (e.g. vitamins, lipoic acids, polyphenols and carotenoids) utilized in RONS-related disease treatment have obtained limited therapeutic effects due to the innate drawback that these organic drugs can participate in only one redox cycle after which they inactivate, i.e. a single dose is quickly depleted in vivo and repetitive doses are still inadequate to control oxidative/nitrosative stress in many cases. Thus, more effective strategies in modulating the balance of RONS need to be developed. In the last few decades, nanotechnology has opened a new chapter in regenerative medicine and a variety of nanosized biomaterials with RONS regulating ability are springing up [54, 55]. Of these, some nanozymes possessing antioxidant activity including platinum [56], manganese [57], fullerene [58], melanin [59] and ceria [23] have shown neuroprotective effects in CNS disorders. Featured with many superiorities such as low cost, low toxicity and simple synthetic procedures, nanoceria is the most extensively explored RONS modulating nanozyme for CNS injury treatment. In addition, it is one of the first nanoparticles utilized as therapeutic agent [60, 61] and even the first material tested as an antioxidant in the space [62]. In this context, nanoceria is selected here as a representative antioxidant nanoparticle. With regenerative ability, nanoceria has an obvious advantage over the other antioxidants and may be a novel option against oxidative/nitrosative stress in the future. Hereinafter, this review discusses the RONS modulating ability of nanoceria, presents up-to-date advances in stroke and neurotrauma treatment and provides some future directions to bridge the gap between experiments and the clinic.

Nanoceria as a RONS modulator

RONS are implicated in many physiological and pathologic processes of aging and disease. They are widely formed particularly through the electron transport chains in mitochondria, including free radicals with unpaired electrons (e.g. superoxide anion (O₂⁻), hydroxyl radical (OH')) and some biologically important non-radicals (e.g. hydrogen peroxide (H₂O₂), peroxynitrite (ONOO⁻)) [63]. These species are essential for regulating internal homeostasis in living systems. However, excessive RONS production can induce oxidative/nitrosative stress, leading to important biomolecules (DNA, protein, lipids) damage and cell death, which is always involved in the early onset of disease [64]. The RONS neutralizing capacities of nanoceria have been discovered for only a dozen years. At the beginning of this century, Rzigalinski et al. [61, 65] serendipitously observed that nanoceria could prolong the lifespan of neuronal cells during their pioneering works, where nanoceria might function as a nanozyme or antioxidant modulating RONS. Since then, the enzyme-like activities and biomedical applications of nanoceria have gained extensive interest in the scientific literature. O₂⁻ is the precursor of most RONS and can be scavenged by SOD, then the SOD mimetic activity of nanoceria has been confirmed. The reaction mechanism follows by Equations (1) and (2) [16]. Further, there was a close correlation between Ce³⁺/Ce⁴⁺ ratio and SOD mimetic efficiency, while nanoceria with higher Ce³⁺/Ce⁴⁺ ratio was more effective than lower ratio ones for O₂⁻ clearance [16, 66].

\[
\begin{align*}
\text{O}_2^- + \text{Ce}^{3+} & \rightarrow \text{O}_2 + \text{Ce}^{4+} \\
\text{O}_2^- + \text{Ce}^{3+} + 2\text{H}^+ & \rightarrow \text{H}_2\text{O}_2 + \text{Ce}^{4+}
\end{align*}
\]  

(1)  

(2)

During the dismutation process of O₂⁻, H₂O₂ is generated and can be degraded by catalase to water and oxygen in aerobic organisms. Soon after the discovery of SOD mimetic activity, nanoceria has also found catalase mimetic activity [17], under which the mechanism follows by Equations (3) and (4) [67]. It is worth noting that the decomposition of H₂O₂ accelerated by nanoceria is also correlated with the Ce³⁺/Ce⁴⁺ ratio but contrary to the SOD mimetic activity. For example, nanoceria with a lower Ce³⁺/Ce⁴⁺ ratio (7%) was more effective in H₂O₂ decomposition than those with a higher Ce³⁺/Ce⁴⁺ ratio (28%) [17]. Nevertheless, in a study comparing the catalytic activity of three different nanostructures (nanorods, nanocubes and nanooctahedra, with Ce³⁺ concentrations of 18.3%, 17.6% and 15.5%, respectively), the decomposition of H₂O₂ was positively correlated to the Ce³⁺/Ce⁴⁺ ratio of nanoceria [68]. These results indicate that in addition to Ce³⁺ concentration, the catalase mimetic activity of nanoceria may be influenced by other factors, e.g. shape and size.
ONOO\textsuperscript{−}, a highly reactive molecule that can induce enzyme inactivation, is generated primarily by the Fenton reaction.

Because O\textsuperscript{2−} and H\textsubscript{2}O\textsubscript{2} are two dominant RONS implicated in disease processes, SOD and catalase are indispensable in the construction of the first line of defense against oxidative stress [69]. In vivo, the combination of NO\textsuperscript{•} and O\textsuperscript{2−} leads to the formation of ONOO\textsuperscript{−}, a highly reactive molecule that can induce enzyme inactivation, DNA damage and lipid peroxidation [70]. Hence, the interaction between ONOO\textsuperscript{−} and nanoceria has been tested. As a result, nanoceria significantly promoted the decay of this destructive molecule, while the decay rate seemed irrelevant to the Ce\textsuperscript{3+}/Ce\textsuperscript{4+} ratio according to the experimental data [71]. In addition, it was reported that nanoceria could scavenge NO\textsuperscript{•} radicals directly or indirectly, which might contribute to less production of ONOO\textsuperscript{−} [72].

Figure 2. The main types of RONS can be modulated by nanoceria via an autocatalytic mechanism of reversible Ce\textsuperscript{4+}/Ce\textsuperscript{3+} transition.

Nanoceria in CNS injury treatment: targeting RONS

The most challenging and leading types of CNS injury are stroke and neurotrauma. Stroke, a brain attack, is induced by either blockage (ischemic stroke) or leakage (hemorrhagic stroke) of blood vessels carrying oxygen and nutrients to the brain [77]. Traumatic injury to the brain or spinal cord shares many similar pathological features with stroke, including ischemia, hemorrhage, blood–brain barrier (BBB) or blood–spinal cord barrier (BSCB) disruption, neuronal death and inflammation. When stroke or neurotrauma occurs, part of the CNS may suffer from ischemia and hypoxia, followed by mitochondrial dysfunction and oxidative/nitrosative stress, leading to further neurological disorders. Additionally, during the injury progression, many other pathways (e.g. excitotoxicity, BBB/BSCB disruption, inflammation, neuronal death) are involved, and extensive crosstalk among these pernicious pathways dramatically increases as shown in Fig. 3 [47, 77]. In this crosstalk, excessive RONS play a pivotal and important role in triggering cell death (e.g. necrosis [78, 79], apoptosis [80], autophagy [81, 82], ferroptosis [83]) and delayed neurological deficits. With excellent RONS modulating ability, nanoceria has been utilized in various CNS-related diseases, ranging from Alzheimer’s disease [24, 84–87], Parkinson’s disease [22, 88], multiple sclerosis [89, 90], amyotrophic lateral sclerosis [76], and have we focused on stroke and neurotrauma [23, 91–105].

Ischemic stroke

Ischemic stroke is the most common subtype of stroke, accounting for more than 80% of all strokes [106, 107]. In a mouse hippocampal brain slice model of ischemia, many nanoparticles localized to the mitochondria, in which the mitochondrial cristae were highly organized after treatment with commercially available nanoceria (Fig 4). Besides, a significant reduction (50%) in ischemic cell death was observed with a modest reduction (15%) in O\textsuperscript{2−} and NO\textsuperscript{•}. Interestingly, 3-nitrotyrosine induced by ONOO\textsuperscript{−} displayed a remarkable reduction (70%), which was far greater than that of O\textsuperscript{2−} and NO\textsuperscript{•}. Considering that both O\textsuperscript{2−} and NO\textsuperscript{•} are precursors of ONOO\textsuperscript{−}, their reductions may contribute to a significant decrease in ONOO\textsuperscript{−}. These results imply that direct or indirect clearance of ONOO\textsuperscript{−} is an important mechanism underlying the neuroprotective effects of nanoceria after ischemia. Moreover, it is worth mentioning that the optimal dose of nanoceria in the study is 1μg/ml, while a higher concentration (2μg/ml) leads to agglomeration in artificial cerebrospinal fluid (CSF), which should be considered in vivo [75]. The agglomeration is a common phenomenon for nanomaterials under physiological conditions, especially in the bloodstream. When the particle size is smaller, the surface-to-volume ratio is larger, and nanoparticles are more likely to agglomerate and adsorb plasma proteins. Then, rapid clearance by macrophages can happen before nanoceria is transported to target cells [108]. In the case of stroke, small particles (<5 nm) are more favorable to cross the BBB into the brain [109, 110]. This dilemma is a major barrier to the design of novel nanomedicine in brain disease treatment. One possible approach for nanoceria overcoming this problem is surface modification to decrease agglomeration and protein adsorption, and simultaneously increase the circulation time in the blood [111].

\[
\text{H}_2\text{O}_2 + \text{Ce(III)} - \text{CeO}_2 \rightarrow \text{H}_2\text{O} + \text{O} = \text{Ce(IV)} \\
\text{H}_2\text{O}_2 + \text{O} = \text{Ce(IV)} - \text{CeO}_2 \rightarrow \text{H}_2\text{O} + \text{O}_2 + \text{Ce(III)} - \text{CeO}_2
\]
Recently, 2.5-nm nanoceria modified with different ratios of citrate acid (CA) and ethylenediamine tetraacetic acid (EDTA) was applied in the brain slice model. As a result, the antioxidant activity of nanoceria was influenced by the surface coatings and nanoparticles with a 1:1 ratio of CA/EDTA exerted a stronger neuroprotective performance. After being injected into a rat model of ischemia–reperfusion 72 h in advance, the CA/EDTA-coated nanoceria achieved a 52% reduction of superoxide accumulation in the hippocampus.

The first case of nanoceria protecting against stroke in vivo has been reported by Kim et al. In this work, uniform 3-nm nanoceria with phospholipid-PEG modification was well dispersed in both phosphate-buffered saline (PBS) and plasma, exhibiting dose-dependent SOD/catalase mimetic activities. After the ischemia–reperfusion rat received a 0.5 mg/kg intravenous injection of nanoceria, the brain infarct area was considerably reduced by 50%. Additionally, the phospholipid-PEG-capped nanoparticles accumulated in the ischemic hemisphere were far more abundant than those in the contralateral hemisphere, suggesting BBB disruption in the damaged area which promoted the entrance of nanoceria into the brain. The higher accumulation of nanoceria in the brain is at least partly due to PEGylation and small particle size, which ameliorate its dispersion and prolong the circulation time in the vasculature. As PEG possesses uncharged hydrophilic residues and high surface mobility, the biocompatibility of PEGylated nanoceria in living systems is significantly improved while the radical scavenging ability is little reduced compared to bare nanoceria.

Although BBB disruption after stroke facilitates nanoparticle permeation into the damaged area of the brain, the passage rate is still very low compared to the total injection dosage. Consequently, the therapeutic effect is quite limited, and a huge portion of nanoparticles may be transported to other organs, possibly inducing side effects.

**Figure 3.** The major pathways involved in CNS injury: oxidative/nitrosative stress, excitotoxicity, ionic imbalance, inflammation, BBB/BSCB disruption and neuronal death. There is extensive crosstalk among these pathways, in which RONS play a critical role. XDH, xanthine dehydrogenase; XO, xanthine oxidase; NOS, nitric oxide synthase; PLA2, phospholipase A2; COX, cyclooxygenase; NMDAr, N-methyl-D-aspartic acid receptor; IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, tumor necrosis factor α.
More importantly, the breakdown of the BBB may allow hazardous molecules and compounds to enter the brain as well, resulting in additional BBB damage and neurological dysfunction. Concerning this issue, functionalized core-shell nanoceria coated with angiopep-2/PEG and loaded with edaravone have achieved simultaneous intracerebral uptake and BBB protection in stroke treatment (Fig. 5). There are three key takeaway points in the nanocomposite system: (i) PEGylation improves biocompatibility, (ii) angiopep-2 targets the BBB and (iii) nanoceria and edaravone scavenge RONS [91]. Angiopep-2 is a specific ligand that can be recognized by low-density lipoprotein receptor-related protein (LRP) overexpressed on cells at the BBB, which facilitates the passage of nanoceria into brain tissue via a transcytosis process [114]. PEGylated nanoceria with angiopep-2 modification obtained much higher accumulation in the brain tissue of healthy rats after injection indicating that angiopep-2 played a critical role in BBB targeting and crossing. Moreover, when loaded with edaravone (a clinical drug applied in stroke treatment), angiopep-2/PEGylated nanoceria exhibited the most protective effects on BBB integrity. The synergetic clearance of RONS by nanoceria and edaravone could alleviate cell death and disassembly of the tight junctions [91].

Notably, ischemic stroke can promote BBB leakage and active angiogenesis of microvessels in the penumbra [115], during which vascular endothelial growth factor (VEGF) is known to play an important role [116]. Interestingly, nanoceria with high surface area and Ce³⁺/Ce⁴⁺ ratio led to robust angiogenesis by modulating oxygen in the intracellular environment [117]. In a study by our group, it was observed that nanoceria enhanced vascularization by triggering high expression of the angiogenic factor VEGF [41], which could shed light on the leakage and angiogenesis of the BBB. In other experiments, nanoceria showed benefits in alleviating BBB disruption after ischemia [92, 93]. By targeting integrin αvβ3 (a cell-surface receptor protein selectively upregulated after ischemia), custom synthesized biotinylated-LXW7-nanoceria could effectively arrive at the ischemic penumbra region and prevent brain damage [92]. LXW7, incorporated into this nanocomposite system, not only facilitates nanoparticles targeting damaged areas but also inhibits integrin αvβ3, preserving the BBB in the early stage [118]. In addition to the BBB, oxidative/nitrosative stress during stroke can damage endothelial cells, inducing vascular lesions and additional cerebral hemorrhage. Nanoceria coated with phosphonic acid PEG copolymers exhibited protective effects by reducing glutamate-induced production of RONS in cerebral endothelial cells [119]. More recently, following an in situ synthetic method, nanoceria was capped with ZIF-8, a porous metal-organic framework comprised imidazolate linkers and zinc ions (Fig. 6). Through a lysosome-mediated endocytic pathway, CeO₂@ZIF-8 could be delivered into cells, after which the outer ZIF-8 shell decomposed and the inner core of CeO₂ was released in the acidic lysosomal environment. The CeO₂@ZIF-8 nanocomposite gained enhanced BBB penetration and RONS clearance, which promoted the stroke treatment compared to the free CeO₂ group [95]. In addition, CeO₂@ZIF-8 also decreased the activation of microglia and astrocytes after ischemia (Fig. 6e) suggesting its involvement in the immune response,
which was consistent with other reports [99, 120–122]. Although CeO$_2$@ZIF-8 was relatively large (240 nm) to some extent, it penetrated the BBB successfully due to the ZIF-8 encapsulation. In another study, 8-nm nanoceria was loaded onto poly-(lactide-co-glycolide)-PEG copolymer matrix to form nanocomposites. These composites resulted in an effective decrease in the infarct volume and edema level of the ischemic brain [93].

**Hemorrhagic stroke**

Hemorrhagic stroke accounts for ~20% of all strokes, including two nontraumatic subtypes, intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH) [106]. In the early stage of hemorrhage, brain damage develops with the formation of hematoma and edema, followed by increased intracranial pressure and inflammatory response, inducing secondary brain injury and further neurological deficits [77, 123, 124]. To date, effective treatment that significantly improves the poor outcomes has yet to be discovered. As a regenerative RONS modulator, nanoceria has achieved considerable effects in animal models of hemorrhagic stroke [97–100].

ICH is characterized by intraparenchymal bleeding followed by the development of hematoma, leading to initial mass effect and subsequent inflammation [125]. However, therapies focused on hematoma resolution have achieved little progress, and surgical removal is difficult due to its special location. Perihematomal inflammation sparking secondary brain injury is a potential target for therapeutic intervention [126]. Nanoceria exhibits anti-inflammatory activity in vitro [120], as well as in vivo ICH models [97, 98]. When PEGylated biocompatible nanoceria was intravenously administered to ICH rats, high accumulation in the hemorrhagic hemisphere was observed, indicating the nanoparticles crossed the damaged BBB. The perihematomal edema caused by ICH was significantly reduced by 68% after treatment with nanoceria, while the hematoma volume was scarcely influenced. In addition, treatment with nanoceria effectively decreased the RONS level and suppressed the recruitment of CD68-positive microglia/macrophages, thus alleviating the inflammation response [97].

After ICH, resident microglia are activated, and a large number of macrophages migrate to the hemorrhagic area due to chemotaxis, followed by phagocytosis of cellular debris and secretion of proinflammatory cytokines. Moreover, with the activation of the nuclear factor-kappa B signaling pathway, inducible nitric oxide synthase is subsequently expressed, resulting in excessive NO generation [127]. Nanoceria can scavenge excessive NO [72, 120], which acts as a dual mediator of neurotransmission (under normal physiological conditions) and inflammation (under pathological conditions) [128]. In light of the anti-inflammatory capacity, nanoceria was loaded on lipid-coated mesoporous silica nanoparticles for theragnosis of ICH (Fig. 7a). In the synthesis, nanoceria was absorbed by magnetic mesoporous silica nanoparticles (FeNP@MSNs) through electrostatic interactions and exquisitely embedded into the 3.2-nm pores of MSNs. After coating with lipids, FeNP@MSNs doped with nanoceria were intracerebrally injected into ICH rats. Magnetic resonance imaging (MRI) clearly showed that these nanoparticles were successfully recruited to...
the perihematomal region and spontaneously internalized by microglia/macrophages (Fig. 7b), which was necessary for attenuating the inflammatory response. As expected, treatment with custom synthesized nanoparticles significantly reduced CD68-positive inflammatory cells (Fig. 7c) and brain edema in the perihematomal region after ICH, which was attributed to the antioxidative capacity of nanoceria. In addition to these therapeutic effects, taking advantage of iron oxide nanoparticles, the nanocomposites increased the efficacy of MRI enhancement in vivo, which was beneficial for ICH diagnosis [98]. Other examples have been reported utilizing nanoceria for MRI contrast enhancement in disease theragnosis [129, 130].

During ICH, RONS accumulation can induce severe damage to white matter, which accounts for at least 50% of the whole human brain volume [131]. A more recent study has reported that PEGylated nanoceria treatment could effectively ameliorate white matter injury and promote the regeneration of myelin sheaths, which surround the axons of neurons and enable the electrical impulses between nerve cells to transmit rapidly. In the ICH group treated with nanoceria, the myelin sheaths at the perihematomal site were thicker than those of the nontreated group [99].

During ICH, RONS accumulation can induce severe damage to white matter, which accounts for at least 50% of the whole human brain volume [131]. A more recent study has reported that PEGylated nanoceria treatment could effectively ameliorate white matter injury and promote the regeneration of myelin sheaths, which surround the axons of neurons and enable the electrical impulses between nerve cells to transmit rapidly. In the ICH group treated with nanoceria, the myelin sheaths at the perihematomal site were thicker than those of the nontreated group [99]. In addition, after intraperitoneal injection of nanoceria into a rat model of sciatic nerve crush injury, more myelinated fibers and thicker myelin sheaths were observed [132]. Since crosstalk among oligodendrocytes, microglia and astrocytes is involved in remyelination [133–135], nanoceria may modulate the crosstalk via RONS clearance. After the injury, nanoceria treatment induces a lower expression of M1 microglia and A1 astrocytes and promotes the differentiation of oligodendrocyte progenitor cells, all of which contribute to remyelination and white matter repair. It is consistent with the report that nanoceria might regulate the phenotype of microglia, i.e. from proinflammatory M1 to anti-inflammatory M2 under pathological conditions [121].

SAH accounts for ~5% of all strokes. Approximately 85% of cases are caused by rupture of an intracranial aneurysm, followed by extravasation of blood into the subarachnoid space. Due to advances in theranostic techniques, the case fatality rates of SAH have markedly decreased during the past several decades. However, many survivors of SAH experience a variety of sequelae, including neurological, cognitive or functional deficits [136]. After blood invades the subarachnoid space, a series of events occur, including a sharp rise in intracranial pressure, a decrease in cerebral blood flow, overproduction of oxyhemoglobin, and other changes in physiology, neurochemistry, molecules and ions. RONS are widely implicated in these damage cascades [137–139].

It was shown that nanoceria synthesized in the aqueous phase and modified with aminocaproic acid/PEG obtained therapeutic effects in the SAH model. In vitro, bespoke ceria nanoparticles with high Ce³⁺ concentrations (43–57%) effectively protected macrophages from death when treated with cytotoxic hemin. The blood clot itself could generate RONS via hemoglobin autooxidation, the Fenton reaction of heme and the toxic effects of thrombin. In vivo, 1-h after SAH onset, nanoceria was intravenously injected into rats resulting in markedly improved neurological scores and survival rates [100]. It is worth noting that nanoceria might contribute to the aggravation of vasospasm via scavenging NO, which is the endothelium-derived relaxing factor.
generated from blood vessels [140]. Recently, nanoceria has been shown to induce NO generation from S-nitrosoglutathione (one of the most biologically abundant NO donors), which overturns the conventional concept that nanoceria acts widely as a NO-scavenging agent [141]. Therefore, the interaction between NO and nanoceria under SAH conditions needs to be more clearly elucidated.

Neurotrauma

Traumatic brain injury (TBI) is the most common cause of death and disability in young people [142]. More than 50 million people experience TBI every year worldwide [143], leading to direct loss of properties and even lives along with indirect impacts on families, friends and society. The primary injury, caused by sudden traumatic damage to the cerebral tissue (vascular breakage and neuronal death), occurs immediately and is almost inevitable. Therefore, therapeutic interventions are mainly focused on the secondary injury, which involves a cascade of biochemical and molecular events, including ionic homeostasis disturbance, release of excitatory neurotransmitters, mitochondrial dysfunction, as well as overproduction of RONS [53].

It was reported that nanoceria improved outcomes after mild TBI. In vitro, 10 nM nanoceria added to cell culture 1 h post-injury significantly reduced neuronal death and attenuated glutamate-mediated
calcium signaling dysregulation. Furthermore, when applied in a rodent model induced by mild lateral fluid percussion to the rat brain, nanoceria protected the activity of endogenous antioxidants (SOD, catalase and glutathione), thus reducing oxidative damage to the brain. Even though repetitive doses were administered and the most effective dose was the highest dosing paradigm (2.5 mg/kg in total), the distribution of 10-nm nanoparticles in the brain was relatively low [101]. As the mimic activity of nanoparticles varies with shape [68], ceria nanorods have exhibited better therapeutic effects on alleviation of brain edema than ceria nanospheres after TBI [102].

The conventional delivery route of intravenous injection is likely to generate potential biosafety issues related to the toxicity of nanoparticles, most of which will be transported to other organs through blood circulation. Therefore, it is essential to explore a new solution for TBI treatment to minimize the potential risk. Non-invasive bandage and patch with nanzymes for topical treatment in TBI have been designed [103, 104]. Although traditional antioxidant-based bandages could decrease infection triggered by RONS and inflammation around the wound area, they maintain efficacy for only a short period and need to be frequently renewed, which is inconvenient for brain trauma. To address this issue, a single-atom Pt/CeO₂-based bandage was constructed by dispersing and trapping single Pt atoms in the CeO₂ (111) matrix, leading to lattice expansion and catalytic activity enhancement. With the help of Pt single-atom catalyst, the Pt/CeO₂ system showed several-fold higher activities in RONS clearance than CeO₂ clusters. In addition, the wound dressing bandage sustained long-term catalytic activity for up to 30 days with little decay. When pasted on the wound of moderate TBI mice for 8 days, it effectively accelerated wound healing to healthy levels while the untreated group only recovered partially [103]. Likewise, the Cr/CeO₂ nanosize-based catalytic patch was utilized for TBI treatment as well as shown in Fig. 9. The monodisperse Cr/CeO₂ nanozyme prepared by the coprecipitation method was loaded onto nickel foams. When doped with Cr³⁺ ions, nanoceria exhibited lattice distortion and a higher Ce³⁺/Ce⁴⁺ ratio, displaying a several-fold enhancement in enzyme-like activity. In addition, the Cr/CeO₂ nanozyme at a 10% doping concentration achieved the highest Ce³⁺/Ce⁴⁺ ratio and the best enzyme-mimetic activity. The patch pasted on TBI mice resulted in excellent wound recovery and improved cognitive function. Furthermore, some of the nanoparticles released from the patch diffused into the brain tissue through the disrupted BBB after TBI, which played a crucial role in modulating RONS and alleviating inflammation [104]. Interestingly, the lattice of nanoceria expanded or contracted when doped with other metal ions because the atomic radius of Ce³⁺ is larger or smaller than that of Ce. Through such a doping method, the Ce³⁺/Ce⁴⁺ ratio of nanoceria could increase, and correspondingly, the enzyme-mimetic activity changes.

Traumatic spinal cord injury, another type of neurotrauma, is an acute injury to the spinal cord caused by external physical impacts similar to TBI [144]. It was initially reported that nanoceria offered neuroprotection to spinal cord neurons isolated from adult rats. Through a microemulsion synthetic process, well-dispersed nanoparticles obtained high biocompatibility and neuroprotection capability in vitro. Nanoceria-treated neurons exhibited normal electrical activity and higher survival compared to the control ones [145]. Similarly, nanoceria was capped by plant extracts [146] or loaded onto biopolymer [147, 148] to improve its biocompatible activity. When cocultured with spinal cord cells, these nanocomposites exhibited auto-regenerative and neuroprotective activity, suggesting the therapeutic potential of nanoceria in spinal cord injury treatment. Furthermore, in a rat model of spinal cord contusion, 20-nm nanoceria was locally injected into the lesion cavity 30 min post-injury. Through modulation of RONS, nanoceria treatment alleviated the inflammatory response by downregulating the expression of inducible nitric oxide synthase and proinflammatory cytokines. The cystic cavity size was substantially reduced (Fig. 10), which consequently contributed to locomotor functional recovery [105]. Locally injected nanoceria could be internalized into microglia around the lesion area and modulate their phenotype from proinflammatory M1 to anti-inflammatory M2, as previously reported [121]. A more effective strategy to target microglia and modulate the inflammatory response could be achieved by coating nanoparticles with microglia-specific antibodies. With conjugation of CD11b antibody, ceria–zirconia nanocomposites were intrathecally administered into the spinal canal of mice, resulting in a significantly higher accumulation in microglia other than astrocytes and neurons [149]. Nanoceria may translocate into neurons through axons, which depends on both axonal integrity and electrical activity. In an experiment conducted on frog sciatic nerve fibers, 120-nm nanoceria translocated along the nerve fibers with a speed closer to the slow axonal transport rate [150], which might contribute to the recovery of the damaged nerves [132]. To be mentioned, the bacterial infection commonly occurs after neurotrauma, which seems innocuous and can be treated by antibiotics in most cases. Interestingly, nanoceria has also exhibited antibacterial activity [151, 152], which might promote the recovery of infected neurons and nerves. Normally, CNS is protected from most infections by immune responses and multilayer barriers. Thus, neuron infections mainly occur in the peripheral nervous system and rarely spread into CNS. However, some infections can innervate the peripheral area, resulting in direct or immune-mediated pathology in CNS. With powerful anti-inflammatory activities [120, 121], nanoceria may be effective against neuroinflammation caused by bacterial or viral infection.

### Challenges and future directions

Hereinabove, we have summarized up-to-date applications of nanoceria in acute CNS injury treatment. In general, studies commonly show significant benefits in animal models of CNS injury, which highlights great opportunities that nanoceria and its related biomaterials could be a potential option against oxidative stress in clinical practice. To move this nanomaterial from the bench to the bedside, some challenges remain to be met, leaving future directions for us to follow.

First, the safety problems concerning nanoceria in vivo must be considered. Apart from its beneficial RONS-scavenging ability, nanoceria exhibits toxic activities in some cases [153–159]. There are some controversial results regarding the anti- and prooxidant activities of nanoceria, which are affected by many factors including particle size, shape, surface chemistry, coatings, local pH and ligands [160]. As these factors greatly influence the biological activity of nanoceria, particles must be well characterized before being delivered into the body, which has been ignored during some works (Table 1).

In an experiment exploring the interaction with OH⁺, nanoceria could convert from exhibiting antioxidant to oxidant activity as the concentration of OH⁺ and nanoparticles increased. At high concentrations, more Ce³⁺ ions were introduced into the system, and nanoceria might catalyze the production of OH⁺ similar to Fe³⁺ in a Fenton reaction [161]. When polymer-coated ceria nanoparticles with different surface charges were added to diverse cell
lines, they exhibited charge-dependent subcellular localization and cytotoxicity. Nanoceria with a positive or neutral charge entered most of the cell lines, while negatively charged particles internalized mostly in the cancer cell lines. Furthermore, the internalization and localization of nanoceria were closely related to its cytotoxicity. After localized in the lysosomes of these cells, nanoceria exhibited obvious toxicity due to the acidic microenvironment; but little toxicity was shown in the cytoplasm or outside the cells [162]. Based on a large body of literature, nanoceria only displays toxicity in animals when injected at high doses (more than tenths of mg of CeO₂ per kg of body weight) [163, 164]. For example, rat brain pro-oxidant effects were reported after peripheral administration of 85 mg/kg nanoceria. Without permeating the BBB, 5-nm nanoceria indirectly decreased the ratio of reduced to oxidized glutathione in the hippocampus and cerebellum, which was an indicator of oxidative stress [165]. To date, there is little evidence of toxicity in response to CNS injury treatment with nanoceria in vivo, as the administration doses are generally very low, mostly lower than 1 mg/kg (Table 1). ‘When it is not toxic, it is not a medicine’, as the saying goes. Every medicine has side effects, what we should focus on is the safe range of concentrations. Thus, nanoceria is typically safe when injected intravenously at therapeutic doses.

Another issue is regarding how to cross the BBB/BSCB. Many biodistribution studies have unanimously found that the major organs of nanoceria accumulation are the liver and spleen, while a minimal fraction could penetrate the BBB/BSCB into the brain or spinal cord [109, 157, 159]. The most characteristic structure of
### Table 1. Applications of nanoceria in various experimental models of CNS injury

| Disease type | Nanoceria size (nm) | $\text{Ce}^{3+}/\text{Ce}^{4+}$ ratio | Coatings | Optimal dosage | Experimental model | Delivery method | Main effects | Date and reference |
|--------------|---------------------|--------------------------------------|----------|----------------|-------------------|----------------|--------------|--------------------|
| Ischemia     | 10 nm               | Not mentioned                        | None     | 1 $\mu$g/ml    | Brain slice       | Cocultured     | 30% reduction of ROS in brain slice. Protecting the structure of mitochondria. | 2011 [75] |
|              | 3 nm                | Not mentioned                        | Phospholipid-PEG | 0.5 mg/kg    | MCAO              | Intravenous    | 50% reduction of infarct volumes in brain. | 2012 [23] |
|              | 4.3 nm              | 34%                                  | Angiopep-2-PEG/edaran-vone | 0.6 mg/kg | MCAO | Intravenous | 30% reduction of infarct volumes in brain. | 2018 [91] |
|              | Not mentioned       | Not mentioned                        | Biotinylated-LXW7 | 0.5 mg/kg | MCAO | Intravenous | Protecting the BBB integrity. | 2018 [92] |
|              | 40 nm               | Not mentioned                        | PEG/PLGA  | 10 mg/kg      | MCAO              | Not mentioned  | Decreasing infarct volumes and brain edema. | 2018 [93] |
|              | 2–2.5 nm            | 43%                                  | Citric acid/EDTA | 60 mg/kg | MCAO | Intraperitoneal | 52% reduction of superoxide in hippocampus. | 2019 [94] |
|              | 20 nm               | Not mentioned                        | ZIF-8    | 0.4 mg/kg     | MCAO              | Intravenous    | 25% reduction of infarct volumes in brain. | 2020 [95] |
| Hemorrhage   | 3 nm                | 43%                                  | Phospholipid-PEG | 0.5 mg/kg | ICH | Intravenous | Decreasing inflammation. | 2017 [97] |
|              | 3 nm                | Not mentioned                        | Phospholipid-PEG | 10 $\mu$g | ICH | Intracerebral | Decreasing inflammation. | 2018 [98] |
|              | 3.4 nm              | 43%                                  | Oleylamine-PEG/DSPE | 0.5 mg/kg | ICH | Intravenous | Decreasing microglia/macrophage recruitment and brain edema. | 2021 [99] |
|              | 3 nm                | 43–57%                               | Aminocaproic acid-PEG | 0.5 mg/kg | SAH | Intravenous | Decreasing inflammation. | 2018 [100] |
| TBI          | 10 nm               | 33%                                  | None     | 0.5 mg/kg     | Mild TBI          | Intravenous    | Reducing calcium dysregulation. | 2020 [101] |
|              | 3 nm/9 nm           | 40%/27%                              | None     | 11.6 mM       | Mild TBI          | Retro-orbital  | Improving cognitive function. | 2021 [102] |
|              | Not mentioned       | Not mentioned                        | None     | Not mentioned | Mild TBI          | Non-invasive topical | Decreasing cell death and cerebral edema. | 2019 [103] |
|              | 8–12 nm             | 27%                                  | None     | Not mentioned | Mild TBI          | Non-invasive topical | Improving cognitive function. | 2021 [104] |
| TSCI         | 19.5 nm             | 34%                                  | None     | 10 $\mu$g     | Spinal cord contusion | Local injected | Decreasing inflammation and cavity size. | 2017 [105] |
|              | 3–5 nm              | Not mentioned                        | None     | 10 nM         | Spinal cord cell | Cocultured     | Improving locomotor function. Neuro-proective effect on the spinal cord neurons. | 2007 [145] |
|              | 15 nm               | Not mentioned                        | Leaf extract | 10 nM       | Spinal cord cell | Cocultured     | Neuro-proective effect on the spinal cord neurons. | 2021 [146] |
|              | 15–25 nm            | Not mentioned                        | Chitosan | Not mentioned | Spinal cord cell | Cocultured     | Neuro-proective effect on the spinal cord neurons. | 2018 [147] |
|              | 40 nm               | Not mentioned                        | PCL/RVL  | Not mentioned | Spinal cord cell | Cocultured     | Neuro-proective effect on the spinal cord neurons. | 2020 [148] |

PEG, polyethylene glycol; EDTA, ethylene diamine tetraacetic acid; PLGA, poly lactic-co-glycolic acid; ZIF, zeolitic imidazolate framework; DSPE, distearoyl phosphoethanolamine; PCL, poly (e-caprolactone); RVL, resveratrol; MCAO, middle cerebral artery occlusion; ICH, Intracerebral hemorrhage; SAH, subarachnoid hemorrhage; TSCI, traumatic spinal cord injury.
the BBB/BSCB is the tight junction, an intercellular barrier between endothelial cells [166], which blocks the paracellular passage of most particles. Under normal conditions, the pore size of tight junctions is speculated to be 1.4–1.8 nm; thus, only particles sized ~1 nm or less can be passively transported through ultra-small pores [167]. Several methods have been proposed to cross the barrier, including paracellular transport, passive diffusion, cell/cell-mediated transport and receptor/adsorptive-mediated transcytosis [168, 169]. Specifically, acute CNS injury is usually accompanied by BBB or BSCB disruption, leading to the transient splitting of the junction, which renders a discrete path for nanoparticles. The most conventional solution to facilitate the penetration of larger nanoparticles into the CNS is surface modification. However, the results are not satisfactory in most cases. Another feasible method bypassing the BBB/BSCB is the direct injection of the nanomedicine into the CSF instead of the bloodstream [170]. Through intrathecal administration, nanoparticles sized <10 nm could passively traffic from CSF to the parenchymal tissue [171]. With the help of CSF flow, nanoceria can be dispersed over the whole CNS. In a previous study, PEGylated ceria–zirconia nanocomposites sized 9 nm were intrathecally injected into mice to determine whether the nanoparticles could reach the spinal cord cells. These nanoparticles were widely delivered into the CNS area from the brain to different regions of the spinal cord, and nanoceria was identified in a large part of the spinal cord cells but only in 7% of the brain cells [149]. However, the biodistribution and pharmacokinetics of nanoceria through intrathecal administration have rarely been reported. Considering that these inorganic nanoparticles may be maintained in living bodies for years, long-term experiments are needed to investigate the biochemical changes in vivo. Therefore, it is essential to explore these aspects more thoroughly.

How much RONS can each dose of nanoceria scavenge? Furthermore, how much scavenging is too much? To solve these problems, the precise molecular mechanisms by which nanoceria scavenges RONS need to be completely elucidated and understood. Most preclinical studies designed for medical applications of nanoceria are mainly focused on the therapeutic outcome rather than the underlying mechanisms of action. Many results indicate that the enzyme-mimetic activity of nanoceria is closely related to the Ce^3+/Ce^4+ ratio, as smaller particles with a larger Ce^3+ fraction present stronger catalytic effects [172]. However, the Ce^3+/Ce^4+ ratio is strongly influenced by the intracellular environment, and what happens to this ratio in the milieu of cells and tissues remains an enigma that has yet to be explored. When internalized into cells, nanoceria was reported to possess a lower Ce^3+/Ce^4+ ratio than outside the cells, indicating a net reduction of its oxidation state in the intracellular environment. In addition, a similar ratio was observed in the organelles (cytoplasm, lysosome), which suggested that the net reduction might occur earlier in the process of cellular internalization [173]. Even though nanoceria protects cells against oxidative/nitrosative stress caused by RONS, it seems more rational to treat nanoceria not as a pure antioxidant, but as a mediator of signal transduction partaking in the process of neuronal death and protection. Hence, nanoceria presents somewhat different effects after localized into cells of different types or physiological states [162]. When delivered into the CNS, nanoceria might change the levels of some neurotransmitters, e.g. dopamine, glutamate and NO. It was reported that nanoceria could oxidize dopamine under acidic conditions in aqueous solutions [19] and in human serum [174], while another study reported its promotive effects on dopamine secretion in PC12 neuronal-like cells [175].

In summary, although some work still needs to be accomplished, nanoceria by virtue of its powerful antioxidant activity is considered to be quite promising in the treatment of CNS injury as well as other RONS-related diseases.

**Funding**

This work was supported by the Pre-research Project (2020XYY15) of Army Medical University.

**Conflicts of interest statement.** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

1. Trovarelli A. Catalytic properties of ceria and CeO2-containing materials. Catal Rev 1996;38:439–520.
2. Trovarelli A, De Leitenburg C, Boaro M, Dolcetti G. The utilization of ceria in industrial catalysis. Catal Today 1999;50:353–67.
3. Trovarelli A. Catalysis by Ceria and Related Materials. Singapore: World Scientific, 2002.
4. Esch F, Fabris S, Zhou L, Montini T, Africh C, Fornasiero P, Comelli G, Rosei R. Electron localization determines defect formation on ceria substrates. Science 2005;309:752–5.
5. Skorodumova NV, Simak SI, Lundqvist BI, Abrikosov IA, Johansson B. Quantum origin of the oxygen storage capability of ceria. Phys Rev Lett 2002;89:166601.
6. Campbell CT, Peden CH. Oxygen vacancies and catalysis on ceria surfaces. Science 2005;309:713–4.
7. Deshpande S, Patil S, Kuchibhatla S, Seal S. Size dependency variation in lattice parameter and valency states in nanocrystalline cerium oxide. Appl Phys Lett 2005;87:133113.
8. Trovarelli A, Llorca J. Ceria catalysts at nanoscale: how do crystal shapes shape catalysis? ACS Catal 2017;7:4716–35.
9. Terrible D, Trovarelli A, Llorca J, de Leitenburg C, Dolcetti G. The synthesis and characterization of mesoporous high-surface area ceria prepared using a hybrid organic/inorganic route. J Catal 1998;178:299–308.
10. Vincent A, Babu S, Heckert E, Dowding J, Hirst SM, Inerbaev TM, Self WT, Reilly CM, Masunov AE, Rahman TS, Seal S. Protonated nanoparticle surface governing ligand tethering and cellular targeting. ACS Nano 2009;3:1203–11.
11. Masui T, Hirai H, Imanaka N, Adachi G, Sakata T, Mori H. Synthesis of cerium oxide nanoparticles by hydrothermal crystallization with citric acid. J Mater Sci Lett 2002;21:489–91.
12. Patil S, Kuiry S, Seal S, Vanfleet R. Synthesis of nanocrystalline ceria particles for high temperature oxidation resistant coating. J Nano Res 2002;4:433–8.
13. Arumugam A, Karthikeyan C, Hamedesh ASH, Gopinath K, Gowri S, Karthika V. Synthesis of cerium oxide nanoparticles using Glorios superba L. leaf extract and their structural, optical and antibacterial properties. Mater Sci Eng C 2015;49:408–15.
14. Wang H, Zhu J-J, Zhu J-M, Liao X-H, Xu S, Ding T, Chen H-Y. Preparation of nanocrystalline ceria particles by sonochemical and microwave assisted heating methods. Phys Chem Chem Phys 2002;4:3794–9.
15. Melchionna M, Trovarelli A, Fornasiero P. Synthesis and properties of cerium oxide-based materials. In: Scire S, Palmisano L (ed.). Cerium Oxide (CeO2): Synthesis, Properties and Applications. Elsevier, 2020, 13–43.
16. Korsvik C, Patil S, Seal S, Self WT. Superoxide dismutase mimetic properties exhibited by vacancy engineered ceria nanoparticles. Chem Commun 2007;10:1056–8.

17. Pirmohamed T, Dowding JM, Singh S, Wasserman B, Heckert E, Karakoti AS, King JE, Seal S, Self WT. Nanoceria exhibit redox state-dependent catalase mimetic activity. Chem Commun (Camb) 2010;46:2736–8.

18. Jiao X, Song H, Zhao H, Bai W, Zhang L, Lv Y. Well-dispersed ceria nanoparticles: promising peroxidase mimetics for H2O2 and glucose detection. Anal Methods 2012;4:3261–7.

19. Asati A, Santana S, Kattanis C, Nath S, Perez JM. Oxidase-like activity of polymer-coated cerium oxide nanoparticles. Angew Chem 2009;121:2344–8.

20. Xu F, Lu Q, Huang Pj, Liu J. Nanoceria as a Dnase I mimicking nanozyme. Chem Commun (Camb) 2019;55:13215–8.

21. Tian Z, Yao T, Qu C, Zhang S, Li X, Qu Y. Photolyase-like catalytic behavior of CeO2. Nano Lett 2019;19:8270–7.

22. Kwon HJ, Kim D, Seo K, Kim YG, Han SI, Kang T, Soh M, Hyeon T. Ceria nanoparticle systems for selective scavenging of mitochondrial, intracellular, and extracellular reactive oxygen species in Parkinson’s disease. Angew Chem Int Ed Engl 2018;57:9408–12.

23. Kim CK, Kim T, Choi IY, Soh M, Kim D, Kim YJ, Jang H, Yang HS, Kim JY, Park HK, Park SP, Park S, Yu T, Yoon BW, Lee SH, Hyeon T. Ceria nanoparticles that can protect against ischemic stroke. Angew Chem Int Ed Engl 2012;51:11039–43.

24. Kwon Hj, Cha MY, Kim D, Kim DK, Soh M, Shin K, Hyeon T, Mook-Jung I. Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer’s disease. ACS Nano 2016;10:2860–70.

25. Tian Z, Li J, Zhang Z, Gao W, Zhou X, Qu Y. Highly sensitive and robust peroxidase-like activity of porous nanorods of ceria and their application for breast cancer detection. Biomaterials 2015;59:116–24.

26. Li H, Liu C, Zeng Y-P, Hao Y-H, Huang J-W, Yang Z-Y, Li R. Nanoceria-mediated drug delivery for targeted photodynamic therapy on drug-resistant breast cancer. ACS Appl Mater Interfaces 2016;8:31510–23.

27. Xiao Y-F, Li J-M, Wang S-M, Yong X, Tang B, Jie M-M, Dong H, Yang X-C, Yang S-M. Cerium oxide nanoparticles inhibit the migration and proliferation of gastric cancer by increasing DHX15 expression. Int J Nanomedicine 2016;11:3023–934.

28. Yu H, Jin F, Liu D, Shu G, Wang X, Qi J, Sun M, Yang P, Jiang S, Ying X, Du Y. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury. Theranostics 2020;10:2342–57.

29. Weng Q, Sun H, Fang C, Xia F, Liao H, Lee J, Wang J, Xie A, Ren J, Guo X, Li F, Yang B, Ling D. Catalytic activity tunable ceria nanoparticles prevent chemotherapy-induced acute kidney injury without interference with chemotherapeutics. Nat Commun 2021;12:1436.

30. Zhang D-Y, Liu H, Li C, Younis MR, Lei S, Yang C, Lin J, Li Z, Huang P. Ceria nanozymes with preferential renal uptake for acute kidney injury alleviation. ACS Appl Mater Interfaces 2020;12:56830–8.

31. Ni D, Wei H, Chen W, Bao Q, Rosenkrans ZT, Barnhart TE, Ferreira CA, Wang Y, Yao H, Sun T, Jiang D, Li S, Cao T, Liu Z, Engle JW, Hu P, Lan X, Cai W. Ceria nanoparticles meet hepatic ischemia-reperfusion injury: the perfect imperfection. Adv Mater 2019;31:1902956.

32. Zhang X, Hu J, Becker KV, Engle JW, Ni D, Cai W, Wu D, Qu S. Antioxidant and C5a-blocking strategy for hepatic ischemia-reperfusion injury repair. J Nanobiotechnol 2021;19:107.

33. Ord D, Yudina T, Fernández-Varo G, Casals E, Reichenbach V, Casals G, González de la Presa B, Sandalinas S, Carvajal S, Puntes V, Jiménez W. Cerium oxide nanoparticles reduce statin, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis. J Hepatol 2016;64:691–8.

34. Niu J, Azfer A, Rogers LM, Wang X, Kolattukudy PE. Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. Cardio Res Rev 2007;73:549–59.

35. Luo L-J, Nguyen DD, Lai J-Y. Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation of ocular hypertension. Theranostics 2021;11:5447–63.

36. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 2006;1:142–50.

37. Luo L-J, Nguyen DD, Lai J-Y. Dually functional hollow ceria nanoparticle platform for intracellular drug delivery: a push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy. Biomaterials 2020;243:119961.

38. Wang Y, Li C, Wan Y, Qi M, Chen Q, Sun Y, Sun X, Fang J, Fu L, Xu L, Dong B, Wang L. Quercetin-loaded ceria nanocomposite potentialise dual-directional immunoregulation via macrophage polarization against periodontal inflammation. Small 2021;17:2101505.

39. Li X, Qi M, Li C, Dong B, Wang J, Wei MD, Imazato S, Du L, Lynch CD, Xu L, Zhou Y, Wang L, Xu HHK. Novel nanoparticles of cerium-doped zeolitic imidazolate frameworks with dual benefits of antibacterial and anti-inflammatory functions against periodontitis. J Mater Chem B 2019;7:6955–71.

40. Ren S, Zhou Y, Zheng K, Xu X, Yang J, Wang X, Miao L, Wei H, Xu Y. Cerium oxide nanoparticles loaded nanofibrous membranes promote bone regeneration for periodontal tissue engineering. Bioact Mater 2022;7:242–53.

41. Xiang J, Li J, He J, Tang X, Dou C, Cao Z, Yu B, Zhao C, Kang F, Yang L, Dong S, Yang X. Cerium oxide nanoparticle modified scaffold interface enhances vascularization of bone grafts by activating calcium channel of mesenchymal stem cells. ACS Appl Mater Interfaces 2016;8:4489–99.

42. Dou C, Li J, He J, Luo F, Yu T, Dai Q, Chen Y, Xu J, Yang X, Dong S. Bone-targeted pH-responsive cerium nanoparticles for ana-bolic therapy in osteoporosis. Bioact Mater 2021;6:4697–706.

43. Li J, Kang F, Gong X, Bai Y, Dai J, Zhao G, Dou C, Cao Z, Liang M, Dong R, Jiang H, Yang X, Dong S. Ceria nanoparticles enhance endochondral ossification–based critical–sized bone defect regeneration by promoting the hypertrophic differentiation of BMSCs via DHX15 activation. FASEB J 2019;33:6378–89.

44. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O’Donnell M, Venkatasubramanian N, Barker-Collo S, Lawes CMM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C. Global and regional burden of stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet 2014;383:245–54.

45. Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil 2006;21:375–8.

46. Lee BB, Cripps RA, Fitzharris M, Wing PC. The global map for traumatic spinal cord injury epidemiology: update 2011, global incidence rate. J Neurotrauma 2014;31:110–6.

47. Lewén A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000;17:871–90.

48. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006;97:1634–58.
86. Cimini A, D’Angelo B, Das S, Gentile R, Benedetti E, Singh V, Monaco AM, Santucci S, Seal S. Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of alpha aggregates modulate neuronal survival pathways. Acta Biomater 2012;8:2056–67.

87. Guan Y, Li M, Dong K, Gao N, Ren J, Zheng Y, Qu X. Ceria/POMs hybrid nanoparticles as a mimicking metalloproteinase for treatment of neurotoxicity of amyloid-beta peptide. Biomaterials 2016;98:92–102.

88. Li Y, Li Y, Wang H, Liu R. "Er3þ codoped cerium oxide upconversion nanoparticles enhanced the enzymelike catalytic activity and antioxidative activity for Parkinson’s disease treatment. ACS Appl Mater Interfaces 2021;13:13968–77.

89. Heckman KL, DeCoteau W, Estevez A, Reed KJ, Costanzo W, Sanford D, Leiter JC, Clauss J, Patchefsky J, Patchefsky AS, Hailstone RK, Erlichman JS. Custom cerium oxide nanoparticles for specific targeting of blood-brain barrier crossing and protection for stroke treatment. ACS Nano 2021;13:10582–96.

90. Eitan E, Hutchison ER, Greig NH, Tweedie D, Pattecky J, Patchefsky AS, Hailstone RK, Erlichman JS. Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain. ACS Nano 2013;7:10582–96.

91. Zhang T, Li C-Y, Jia J-F, Chi J-S, Zhou D, Li J-Z, Liu X-M, Zhang J, Yi L. Combination therapy with LX7W and ceria nanoparticles protects against acute cerebral ischemia/reperfusion injury in rats. Curr Med Sci 2018;38:144–52.

92. Gao Y, Chen X, Liu H. A facile approach for synthesis of nano-CeO2 particles loaded co-polymer matrix and their colossal role for blood-brain barrier permeability in cerebral ischemia. J Photochem Photobiol B 2018;187:184–9.

93. Estevez AY, Ganesana M, Trentini JF, Olson JE, Li G, Boateng YO, Lipps JM, Yablonski SER, Donnelly WT, Leiter JC, Erlichman JS. Antioxidant enzyme-mimetic activity and neuroprotective effects of cerium oxide nanoparticles stabilized with various ratios of citric acid and EDTA. Biomolecules 2019;9:562.

94. He L, Huang G, Liu H, Sang C, Liu X, Chen T. Highly bioactive zeolitic imidazolate framework-8-capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke. Sci Adv 2020;6:eeya9751.

95. Zhou D, Fang T, Lu L-Q, Yi L. Neuroprotective potential of cerium oxide nanoparticles for focal cerebral ischemic stroke. J Huazhong Univ Sci Technol (Med Sci) 2016;36:480–8.

96. Kang D-W, Kim CK, Jeong H-G, Soh M, Kim T, Choi I-Y, Ki S-K, Kim DY, Yang W, Hyeon T, Lee S-H. Biocompatible custom ceria nanoparticles against reactive oxygen species resolve acute inflammatory reaction after intracerebral hemorrhage. Nano Res 2017;10:2743–60.

97. Cha BG, Jeong H-G, Kang D-W, Nam M-J, Kim CK, Kim DY, Choi I-Y, Ki SK, Kim SI, Han J, Kim J, Lee S-H. Customized lipid-coated magnetic mesoporous silica nanoparticle doped with ceria nanoparticles for theragnosis of intracerebral hemorrage. Nano Res 2018;11:3582–92.

98. Zheng J, Lu J, Mei S, Wu H, Sun Z, Fang Y, Xu S, Wang X, Shi L, Xu W, Chen S, Yu J, Liang F, Zhang J. Ceria nanoparticles ameliorate white matter injury after intracerebral hemorrhage: microglia-astrocyte involvement in remyelination. J Neuroinflammation 2021;18:43.

99. Jeong H-G, Cha BG, Kang D-W, Kim DY, Ki SK, Kim SI, Han JH, Yang W, Kim CK, Kim J, Lee S-H. Ceria nanoparticles synthesized with aminocaproic acid for the treatment of subarachnoid hemorrhage. Stroke 2018;49:3030–8.

100. Bailey ZS, Nilson E, Bates JA, Oyalew A, Hockey KS, Sajja V, Thorpe C, Rogers H, Dunn B, Frey AS, Billings MJ, Sholar CA, Herramendza A, Kamar C, VandeVord P, Rzgilinski BA. Cerium oxide nanoparticles improve outcome after and mild traumatic brain injury. J Neurotrauma 2020;37:1452–62.

101. Youn DH, Tran NM, Kim BJ, Kim JY, Jeon JF, Yoo H. Shape effect of cerium oxide nanoparticles on mild traumatic brain injury. Sci Rep 2021;11:15571.

102. Yan R, Sun S, Yang J, Long W, Wang J, Mu X, Li Q, Hao W, Zhang S, Liu H, Gao Y, Ouyang L, Chen J, Liu S, Zhang X-D, Ming D. Nanomine-based bandage with single-atom catalysis for brain trauma. ACS Nano 2019;13:11552–60.

103. Zheng S, Liu Y, Sun S, Wang J, Li Q, Yan R, Gao Y, Liu H, Liu S, Hao W, Dai H, Liu C, Sun Y, Long W, Mu X, Zhang XD. Catalytic patch with redox Cr/CeO2 nanomine of noninvasive intervention for brain trauma. Theranostics 2021;11:2806–21.

104. Kim J-W, Mahapatra C, Hong J-Y, Kim MS, Leong KW, Kim H-W, Hyun JK. Functional recovery of contused spinal cord in rat with the injection of optimal-dosed cerium oxide nanoparticles. Adv Sci (Wein) 2017;4:1700034.

105. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009;8:355–69.

106. Benjamire EJ, Muntrer P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djuosse L, Elkind MSV, Ferguson JF, Fournage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Litchman JH, Longenecker CT, Loop MS, Lutey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O’Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Sparano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wills KS, Virani SS, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019;139:e55–e528.

107. Patil S, Sandberg A, Heckert E, Self W, Seal S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials 2007;28:4600–7.

108. Hadas SS, Butterfield DA, Sultana R, Tseng MT, Dan M, Florence RL, Unrine JM, Graham UM, Wu P, Grukie EA, Yokel RA. Brain distribution and toxicological evaluation of a systematically delivered engineered nanoscale ceria. Toxicol Sci 2010;116:562–76.

109. Yokel RA, Tseng MT, Dan M, Unrine JM, Graham UM, Wu P, Grukie EA. Biodistribution and biopersistence of ceria engineered nanomaterials: size dependence. Nanomedicine 2013;9:398–407.

110. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002;23:1553–61.

111. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 2016;99:28–51.
113. Karakoti AS, Singh S, Kumar A, Malinska M, Kuchibhatla S, Wozniak K, Self WT, Seal S. PGylated nanoceria as radical scavenger with tunable redox chemistry. J Am Chem Soc 2009;131:14144–5.

114. Demeule M, Currie JC, Bertrand Y, Ché C, Nguyen T, Régnée A, Gabathuler R, Castaigne JP, Béliveau R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 2008;106:1534–44.

115. Krupinski J, Kauza J, Kumar P, Kumar S, Wang JM. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994;25:1794–8.

116. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, Bruggen N, Chopp M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000;106:829–38.

117. Das S, Singh S, Dowling JM, Oommen S, Kumar A, Sayle TXT. Anti-inflammatory properties of cerium oxide nanoparticles through the modulation of oxygen in intracellular environments. Biomaterials 2012;33:7746–55.

118. Shimamura N, Matchett G, Yatsushige H, Calvert JW, Ohkuma H, Zhang J. Inhibition of integrin αvβ3 ameliorates focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Stroke 2006;37:1902–9.

119. Goujon G, Baldim V, Roques C, Bia N, Seguin J, Palmier B, Graillet A, Loubat C, Mignet N, Margaill I, Berret J-F, Berat-Bertharet V. Antioxidant activity and toxicity study of cerium oxide nanoparticles stabilized with innovative functional copolymers. Adv Healthcare Mater 2021;10:2100059.

120. Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, Reilly CM. Anti-inflammatory properties of cerium oxide nanoparticles. Small 2009;5:2848–56.

121. Zeng F, Wu Y, Li X, Ge X, Guo Q, Lou X, Cao Z, Hu B, Long NJ, Mao Y, Li C. Custom-made ceria nanoparticles show a neuroprotective effect by modulating phenotypic polarization of the microglia. Angew Chem 2018;130:5910–4.

122. Hekmatimoghadam S, Iman M, Shahdadi Sardo H, Jebali A, Gelatin hydrogel containing cerium oxide nanoparticles covered by interleukin-17 aptamers as an anti-inflammatory agent for brain inflammation. J Neuroinmunol 2019;326:79–83.

123. Van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007;369:306–18.

124. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurool 2006;5:53–63.

125. Azzuila AR, Diringer MN, Derdeyn CP, Powers WJ. Progression of mass effect after intracerebral hemorrhage. Stroke 1999;30:1167–73.

126. Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke 2011;42:1781–6.

127. Chen J-C, Ho F-M, Pei-Dawn Lee C, Chen C-P, Jeng K-CG, Hsu H-B, Lee S-T, Tung WW, Lin W-W. Inhibition of iNOS gene expression by quercetin is mediated by the inhibition of IkappaB kinase, nuclear factor-kappa B and STAT1, and depends on heme oxygenase-1 induction in mouse BV-2 microglia. Eur J Pharmacol 2005;521:9–20.

128. Ding R, Chen Y, Yang S, Deng X, Fu Z, Feng L, Cai Y, Du M, Zhou Y, Tang Y. Blood-brain barrier disruption induced by hemoglobin in vivo: involvement of up-regulation of nitric oxide synthase and peroxynitrite formation. Brain Res 2014;1571:25–38.

129. Wu Y, Zhang R, Tran HD, Kurniawan ND, Moonshi SS, Whittaker AK, Ta HT. Chitosan nanococktails containing both ceria and superparamagnetic iron oxide nanoparticles for reactive oxygen species-related theranostics. ACS Appl Nano Mater 2021;4:3604–18.

130. Eriksson P, Tal AA, Skallberg A, Brommsson C, Hu Z, Boyd RD, Olovsson W, Fairley N, Abrikosov IA, Zhang X, Uvdal K. Cerium oxide nanoparticles with antioxidant capabilities and gadolinium integration for MRI contrast enhancement. Sci Rep 2018;8:6999.

131. Smith E, Guroi M, Eng J, Engel C, Nguyen T, Rosand J, Greenberg S. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 2004;63:1606–12.

132. Soluk M, Mahmoudi F, Abdolmaleki A, Asadi A, Sabahi Namini A. Cerium oxide nanoparticles as a new neuroprotective agent to promote functional recovery in a rat model of sciatric nerve crush injury. Br J Neurosurg 2020;1–6.

133. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CI, Fields RD. Astrocytes promote myelination in response to electrical impulses. Neuron 2006;49:823–32.

134. Hughes AN, Appel B. Microglia phagocytose myelin sheaths to modify developmental myelination. Nat Neurosci 2002;2009;3:1055–66.

135. Domingues HS, Portugal CC, Socrado R, Relvas JB. Oligodendrocyte, astrocyte, and microglia crosstalk in myelin development, damage, and repair. Front Cell Dev Biol 2016;4:79.

136. Nieuwkamp DJ, Setz LE, Algra A, Linn FHH, de Rooij NK, Rinkel GJE. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol 2009;8:635–42.

137. Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol 2014;10:44–58.

138. Cahill J, Cahill WJ, Calvert JW, Calvert JH, Zhang JH. Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2006;26:1341–53.

139. Sebha FA, Hou J, Pluta RM, Zhang JH. The importance of early brain injury after subarachnoid hemorrhage. Prog Neurobiol 2012;97:14–37.

140. Ignarro LJ, Buga GM, Wood KS, Byrnes RR, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987;84:9265–9.

141. Luo Z, Zhou Y, Yang T, Gao Y, Kumar P, Chandrawati R. Ceria nanoparticles as an unexpected catalyst to generate nitric oxide from S-nitrosoglutathione. Small 2022;18:2105762.

142. Ghajar J. Traumatic brain injury. Lancet 2000;356:923–9.

143. Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Boli A, Bragge P, Brazinova A, Buki A, Chesnut RM, Citerio G, Coburn M, Cooper DJ, Crowder AT, Czeiter E, Czosnyka M, Diaz-Arrastia R, Dreier JP, Duhaime A-C, Ercole A, van Essen TA, Feigin VL, Gao G, Giacino J, Gonzalez-Lara LE, Gruen RL, Gupta D, Haringsa JA, Hill S, Jiang Y-J, Ketharanathan N, Kompanje EJO, Lanyon L, Laureys S, Lecky F, Levin H, Lingsma HF, Majoile M, Majdan M, Manley G, Marsteller J, Mascia L, McFadyen C, Mondello S, Newcombe V, Polatoe A, Parizel PM, Peul W, Piercy J, Polinder S, Rasmussen TE, Rossaint R, Smielewski P, Soderberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derberg J, Stanworth SJ, Stein MB, von Steinbu¨ chel N, Stewart W, Smielewski P, So¨ derber
Ahuja CS, Wilson JR, Nori S, Kotter MRN, Druschel C, Curt A, Fehlings MG. Traumatic spinal cord injury. *Nat Rev Dis Primers* 2017;3:17018.

Das M, Patil S, Bhargava N, Kang JF, Riedel LM, Seal S, Hickman JJ. Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons. *Biomaterials* 2007;28:1918–25.

Yiling W, Murakonda GK, Jarubula R. Application of green-synthesized cerium oxide nanoparticles to treat spinal cord injury and cytotoxicity evaluation on paediatric leukaemia cells. *Mater Res Express* 2021;8:075006.

Fang X, Song H. Synthesis of cerium oxide nanoparticles loaded on chitosan for enhanced auto-catalytic regenerative ability and biocompatibility for the spinal cord injury repair. *J Photochem Photobiol B* 2019;191:83–7.

Dong L, Kang X, Ma Q, Xu Z, Sun H, Hao D, Chen X. Novel approach for efficient recovery for spinal cord injury repair via biofabricated nano-cerium oxide loaded PCL with resveratrol to improve in vitro biocompatibility and autorecovery abilities. *Dose Response* 2020;18:1559328520933518.

Choi B, Soh M, Manandhar Y, Kim D, Han SJ, Baik S, Shin K, Koo S, Kwon HJ, Ko G, Oh J, Hwang H, Hyeon T, Lee SJ. Highly selective microglial uptake of ceria-zirconia nanoparticles for enhanced analgesic treatment of neuropathic pain. *Nanoscale* 2019;11:19437–47.

Kastrinaki G, Samsouris C, Kosmidis EK, Papaioannou E, Konstandopoulos AG, Theophilidis G. Assessing the axonal translocation of CeO$_2$ and SiO$_2$ nanoparticles in the sciatic nerve fibers of the frog, *an ex vivo* electrophysiological study. *Int J Nanomedicine* 2015;10:7089–96.

Shah V, Shah S, Shah H, Rispoli FJ, McDonnell KT, Workeneh S, Karakoti A, Kumar A, Seal S. Antibacterial activity of polymer coated cerium oxide nanoparticles. *PLoS One* 2012;7:e47827.

Sun Y, Sun X, Li X, Li W, Li C, Zhou Y, Wang L, Dong B. A versatile nanocomposite based on nanoceria for antibacterial enhancement and protection from aPDT-aggravated inflammation via modulation of macrophage polarization. *Biomaterials* 2021;268:120614.

Lin W, Huang YW, Zhou XD, Ma Y. Toxicity of cerium oxide nanoparticles in human lung cancer cells. *Int J Toxicol* 2006;25:451–7.

Thill A, Zeyons O, Spalla O, Chauvat F, Rose J, Auffan M, Flank AM. Cytotoxicity of CeO$_2$ nanoparticles for *Escherichia coli*. Physico-chemical insight of the cytotoxicity mechanism. *Environ Sci Technol* 2006;40:6151–6.

Park EJ, Choi J, Park YK, Park K. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells. *Toxicology* 2008;245:90–100.

Xia T, Kovochich M, Lioni M, Madler L, Gilbert B, Shi H, Yeh Ji, Zink Ji, Nel AE. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. *ACS Nano* 2008;2:2121–34.

Yokel RA, Florence RL, Unrine JM, Tseng MT, Graham UM, Wu P, Grulke EA, Sultana R, Hardas SS, Butterfeld DA. Biodistribution and oxidative stress effects of a systemically-administered 5 nm ceria 30 days after exposure. *Environ Sci Nano* 2019;3:234–48.

Yokel RA, Hussain S, Garantziotis S, Demokritou P, Castranova V, Cassee FR. The yin: an adverse health perspective of nanoceria: uptake, distribution, accumulation, and mechanisms of its toxicity. *Environ Sci Nano* 2014;1:406–28.